Implementation of post-discharge malaria chemoprevention (PDMC) in Benin, Kenya, Malawi, and Uganda: stakeholder engagement meeting report.
Jenny Hill, PDMC Saves Lives Consortium
https://pubmed.ncbi.nlm.nih.gov/38539181/Actively Recruiting
Led by Institut de Recherche Clinique du Benin · Updated on 2026-08-12
648
Participants Needed
2
Research Sites
4 weeks
Total Duration
Researchers are conducting implementation trials in Benin to evaluate different ways of delivering post-discharge malaria chemoprevention PDMC to children under 10 years old who were hospitalized with severe anaemia or severe malaria. The study aims to find effective delivery methods and adherence support to reduce hospital readmissions and deaths after discharge. This trial is a phase 4 cluster randomized study designed to provide evidence to support national health policies and scaling up PDMC in malaria-endemic areas. Participants will receive three courses of a 3-day PDMC treatment with dihydroartemisinin-piperaquine at weeks 2, 6, and 10 after hospital discharge. The study compares two community delivery strategies one where caregivers receive all PDMC drugs at discharge with monthly home visit reminders, and another where community health workers deliver the drugs at home with SMS or phone reminders. A control group will receive the drugs at discharge without additional adherence support. All children also receive standard hospital care for severe anaemia or malaria during admission. Throughout the 14 weeks following discharge, children will be monitored for adherence to PDMC and health outcomes including hospital readmissions, clinic visits, and mortality. Researchers will collect data through household visits, passive surveillance, and unannounced home visits to check medication adherence. The study also includes economic, acceptability, and feasibility evaluations to assess cost-effectiveness, stakeholder views, and practical aspects of implementing PDMC delivery methods. The total study duration spans 36 months, including preparation, recruitment, follow-up, and data analysis.
CONDITIONS
Post-discharge Malaria Chemoprevention Implementation Trial in Benin
M
Manfred Accrombessi, MD, PhD
A
Achille Massougbodji, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Institut de Recherche Clinique du Benin
Lead Sponsor
Liverpool School of Tropical Medicine
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 14 weeks
Participants receive three courses of the PDMC drug dihydroartemisinin-piperaquine at weeks 2, 6, and 10 after hospital discharge. Delivery and adherence support methods vary by study group, including drug provision at discharge with reminders or home delivery by community health workers.
Monthly follow-ups and unannounced home visits after each PDMC course
Duration - Up to 14 weeks post-discharge
Participants are monitored for health outcomes such as hospital readmissions, clinic visits, and mortality through passive surveillance and an end-of-study visit around week 14 post-discharge.
End-of-study visit and passive monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Jenny Hill, PDMC Saves Lives Consortium
https://pubmed.ncbi.nlm.nih.gov/38539181/Institut de Recherche Clinique du Benin
Lead Sponsor
Liverpool School of Tropical Medicine
Collaborating Sponsor